Press Release: Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
29.09.2022 - Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 ...
Eva Schaefer Jansen Corentine Driancourt Felix Lauscher Georged Yancopoulos Hannah Kwagh Nathalie Pham
Source: wallstreet-online.de